wherein the product resulting from the at least three of (i)-(v) comprises Synagis® and is suitable for administration to a human and has a DNA concentration of ≤ 0.5 pg/mg; and wherein the method does not comprise adding benzonase to the composition.

4. The method of any of claims 1 to 3, wherein the method does not comprise adding an exogenous nuclease to the composition.

5. The method of claim 1, further comprising a ~~virus~~ viral inactivation process.

6. The method of any of claims 2, 3, or 5, wherein the ~~virus~~ viral inactivation process comprises incubating the composition at a pH less than 4.0.

~~7. The method of claim 1, wherein the antibody is an IgG.~~

~~8.~~7. The method of any of claims 1 to 6, wherein the affinity purification process comprises a Protein A purification process.

~~9.~~8. The method of claim 1, wherein the ion exchange chromatography process is a cation exchange chromatography process.

~~10.~~9. The method of any of claims 2, 3, or ~~9~~8, wherein the cation exchange process comprises adsorbing the ~~antibody~~ Synagis® to a cationic resin selected from the group consisting Capto S, S-Sepharose FF, and Poros 50 HS.

~~11.~~10. The method of any of claims 1 to 9, further comprising a second ion exchange process.

~~12.~~11. The method of claim ~~11~~10, wherein the second ion exchange process is an anion exchange chromatography process.

~~13.~~12. The method of claim ~~12~~11, wherein the anion exchange process comprises passing ~~the antibody~~ Synagis® through an anionic membrane selected from the group consisting of Super Q, Natrix Q, Chromasorb Q and Mustang Q.

~~14.~~13. The method of any of claims 1 to 12, wherein the final product has an antibody yield of >80% (mol/mol) ~~and/or wherein the DNA concentration of the final product is ≤ 200 ng/mg~~.

~~15.~~14. The method of any of claims 1 to 13, wherein the composition is selected from the group consisting of serum of immunized animals, ascites fluid, hybridoma or myeloma supernatants, conditioned media derived from culturing a recombinant cell line, cell extracts of immunoglobulin producing cells, and a bioreactor preparation.

~~16.~~15. The method of any of claims 1 to 14, wherein the composition has a volume greater than 100 liters.

~~17.~~16. The method of any of claims 1 to 15, wherein the composition has a volume greater than 1000 liters.

~~18.~~17. The method of any of claims 1 to 16, wherein the process of (ii) occurs after the process of (i).

~~19.~~18. The method of any of claims 1 to 17, wherein the process of (iii) occurs after the process of (ii).

~~20.~~19. The method of any of claims 1 to 18 wherein Synagis® comprises:

a heavy chain having the amino acid sequence SEQ ID NO: 1 and a light chain having the amino acid sequence of SEQ ID NO: 6;

a heavy chain variable region of SEQ ID NO:1 or SEQ ID NO: 2 and a light chain variable region of the light chain SEQ ID NO:6; or

a H1 complementarity determining region (CDR) having the amino acid sequence TSGMSVG (SEQ ID NO: 3), a H2 CDR having the amino acid sequence DIWWDDKKDYNPSLKS (SEQ ID NO: 4), a H3 CDR having the amino acid sequence SMITNWYFDV (SEQ ID NO: 5); a L1 CDR having the amino acid sequence KCQLSVGYMH (SEQ ID NO: 7), a L2 CDR having the amino acid sequence DTSKLAS (SEQ ID NO: 8), and a L3 CDR having the amino acid sequence FQGSGYPFT (SEQ ID NO:9).